Emcyt

(Estramustine)

Phase 3Small molecule

PPharmacia and Upjohn

Emcyt is one of 204 small molecule programs targeting Prostate Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

203

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Prostate AdenocarcinomaActive, not recruiting

Prostate CarcinomaActive, not recruiting

AdenocarcinomaActive, not recruiting

Metastatic Prostate CancerActive, not recruiting

Breast CancerActive, not recruiting

Prostate CancerActive, not recruiting

Prostate AdenocarcinomaPhase 1

Active, not recruiting

Prostate CarcinomaPhase 1/Phase 2

Active, not recruiting

AdenocarcinomaPhase 2

Active, not recruiting

Metastatic Prostate CancerPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Prostate CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Emcyt

PPharmacia and Upjohn

Phase 3

2 2

Halaven

Eisai

Preclinical

38 3

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 4

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Spravato

WWim Janssens

Preclinical

2 7

Tricor

JJagotec

Preclinical

1 8

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Chantix

PPrism Pharmaceuticals

Preclinical

1 10

Systemic Therapy

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prostate Cancer8 trials

Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer

Terminated·TThe University of Texas Health Science Center, Houston·Phase 2·NCT02560051·19 enrolled

Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT00151086·33 enrolled

Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer

Terminated·TThe University of Texas Health Science Center, Houston·Phase 2·NCT02494713·4 enrolled

Show 5 more trials

Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00016913·34 enrolled

Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer

Completed·—·Phase 2·NCT01250717·28 enrolled

Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193271·30 enrolled

S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy

Completed·SSWOG Cancer Research Network·Phase 3·NCT00004001·770 enrolled

Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy.

Completed·UUniversity of Southern California·Phase 2·NCT00183924·20 enrolled

Adenocarcinoma2 trials

Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00151060·28 enrolled

Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00151073·28 enrolled

Breast Cancer2 trials

Efficacy and Safety of Estracyt® in Metastatic Breast Cancer

Withdrawn·—·Phase 2·NCT02853071

Evaluation of the Efficacy of Estramustine in Patient With Breast Cancer Progression After Treatment With Aromatase Inhibitor.

Completed·IInstitut de Cancérologie de Lorraine·Phase 2·NCT02866955·100 enrolled

Prostate Carcinoma2 trials

Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193193·100 enrolled

Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00038246·40 enrolled

Prostate Adenocarcinoma1 trial

Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00038168·14 enrolled

3 more indications

Metastatic Prostate Cancer1 trial

S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

Completed·SSWOG Cancer Research Network·Phase 2·NCT00028769·41 enrolled

Safety and Efficacy1 trial

Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer

Completed·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 2·NCT00541281·150 enrolled

Withdrawal1 trial

Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment

Completed·—·Phase 2·NCT00165399·62 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

EMCYT

NDA NDA018045

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Estramustine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Estramustine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Estramustine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA018045). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Pharmacia and Upjohn company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PPharmacia and Upjohn

Emcyt

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prostate Cancer8 trials

Adenocarcinoma2 trials

Breast Cancer2 trials

Prostate Carcinoma2 trials

Prostate Adenocarcinoma1 trial

Metastatic Prostate Cancer1 trial

Safety and Efficacy1 trial

Withdrawal1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News